The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Myeloid Leukaemia Therapeutics Market Research Report 2025
Synopsis
Global Acute Myeloid Leukaemia Therapeutics market is projected to reach US$ 7130.2 million in 2029, increasing from US$ 3500 million in 2022, with the CAGR of 10.7% during the period of 2023 to 2029.
Key companies engaged in the Acute Myeloid Leukaemia Therapeutics industry include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Acute Myeloid Leukaemia Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Acute Myeloid Leukaemia Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Acute Myeloid Leukaemia Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Novartis AG
Celgene Corporation
Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals
Boehringer Ingelheim International GmbH
Johnson & Johnson
Gilead Sciences, Inc.
Amgen Inc.
Takeda Pharmaceutical Company Limited
Sunesis Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hypomethylating Agents
Others
Segment by Application
Specialty Clinics
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Acute Myeloid Leukaemia Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Acute Myeloid Leukaemia Therapeutics market is projected to reach US$ 7130.2 million in 2029, increasing from US$ 3500 million in 2022, with the CAGR of 10.7% during the period of 2023 to 2029.
Key companies engaged in the Acute Myeloid Leukaemia Therapeutics industry include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Acute Myeloid Leukaemia Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Acute Myeloid Leukaemia Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Acute Myeloid Leukaemia Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Novartis AG
Celgene Corporation
Astellas Pharma Inc.
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals
Boehringer Ingelheim International GmbH
Johnson & Johnson
Gilead Sciences, Inc.
Amgen Inc.
Takeda Pharmaceutical Company Limited
Sunesis Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hypomethylating Agents
Others
Segment by Application
Specialty Clinics
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Acute Myeloid Leukaemia Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Hypomethylating Agents
1.2.6 Others
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukaemia Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Specialty Clinics
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukaemia Therapeutics Market Perspective (2018-2029)
2.2 Acute Myeloid Leukaemia Therapeutics Growth Trends by Region
2.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Myeloid Leukaemia Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Acute Myeloid Leukaemia Therapeutics Market Dynamics
2.3.1 Acute Myeloid Leukaemia Therapeutics Industry Trends
2.3.2 Acute Myeloid Leukaemia Therapeutics Market Drivers
2.3.3 Acute Myeloid Leukaemia Therapeutics Market Challenges
2.3.4 Acute Myeloid Leukaemia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukaemia Therapeutics Players by Revenue
3.1.1 Global Top Acute Myeloid Leukaemia Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Acute Myeloid Leukaemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Myeloid Leukaemia Therapeutics Revenue
3.4 Global Acute Myeloid Leukaemia Therapeutics Market Concentration Ratio
3.4.1 Global Acute Myeloid Leukaemia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukaemia Therapeutics Revenue in 2022
3.5 Acute Myeloid Leukaemia Therapeutics Key Players Head office and Area Served
3.6 Key Players Acute Myeloid Leukaemia Therapeutics Product Solution and Service
3.7 Date of Enter into Acute Myeloid Leukaemia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukaemia Therapeutics Breakdown Data by Type
4.1 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Type (2024-2029)
5 Acute Myeloid Leukaemia Therapeutics Breakdown Data by Application
5.1 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Acute Myeloid Leukaemia Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
6.2 North America Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2018-2023)
6.4 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
7.2 Europe Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2018-2023)
7.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
9.2 Latin America Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.1.4 Pfizer Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Introduction
11.2.4 Novartis AG Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Detail
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.3.5 Celgene Corporation Recent Development
11.4 Astellas Pharma Inc.
11.4.1 Astellas Pharma Inc. Company Detail
11.4.2 Astellas Pharma Inc. Business Overview
11.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.4.4 Astellas Pharma Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.4.5 Astellas Pharma Inc. Recent Development
11.5 Daiichi Sankyo Company, Limited
11.5.1 Daiichi Sankyo Company, Limited Company Detail
11.5.2 Daiichi Sankyo Company, Limited Business Overview
11.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Introduction
11.5.4 Daiichi Sankyo Company, Limited Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.5.5 Daiichi Sankyo Company, Limited Recent Development
11.6 Jazz Pharmaceuticals
11.6.1 Jazz Pharmaceuticals Company Detail
11.6.2 Jazz Pharmaceuticals Business Overview
11.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Introduction
11.6.4 Jazz Pharmaceuticals Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.6.5 Jazz Pharmaceuticals Recent Development
11.7 Boehringer Ingelheim International GmbH
11.7.1 Boehringer Ingelheim International GmbH Company Detail
11.7.2 Boehringer Ingelheim International GmbH Business Overview
11.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Introduction
11.7.4 Boehringer Ingelheim International GmbH Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.7.5 Boehringer Ingelheim International GmbH Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Introduction
11.8.4 Johnson & Johnson Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 Gilead Sciences, Inc.
11.9.1 Gilead Sciences, Inc. Company Detail
11.9.2 Gilead Sciences, Inc. Business Overview
11.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.9.4 Gilead Sciences, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.9.5 Gilead Sciences, Inc. Recent Development
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Detail
11.10.2 Amgen Inc. Business Overview
11.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.10.4 Amgen Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.10.5 Amgen Inc. Recent Development
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Takeda Pharmaceutical Company Limited Company Detail
11.11.2 Takeda Pharmaceutical Company Limited Business Overview
11.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Introduction
11.11.4 Takeda Pharmaceutical Company Limited Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.11.5 Takeda Pharmaceutical Company Limited Recent Development
11.12 Sunesis Pharmaceuticals, Inc.
11.12.1 Sunesis Pharmaceuticals, Inc. Company Detail
11.12.2 Sunesis Pharmaceuticals, Inc. Business Overview
11.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.12.4 Sunesis Pharmaceuticals, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.12.5 Sunesis Pharmaceuticals, Inc. Recent Development
11.13 Agios Pharmaceuticals, Inc.
11.13.1 Agios Pharmaceuticals, Inc. Company Detail
11.13.2 Agios Pharmaceuticals, Inc. Business Overview
11.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Introduction
11.13.4 Agios Pharmaceuticals, Inc. Revenue in Acute Myeloid Leukaemia Therapeutics Business (2018-2023)
11.13.5 Agios Pharmaceuticals, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
